Login
Navigate Fool.com
Will ACOR beat
the market?
Community Rating: 3 Stars: Appealing

35.34 0.09 (0.26%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $35.58
Previous Close $35.25
Daily Range $33.56 - $35.58
52-Week Range $27.51 - $39.95
Market Cap $1.5B
P/E Ratio 90.38
Dividend (Yield) $0.00 (0.0%)
Volume 94,720
Average Daily Volume 472,374
Current FY EPS $0.51

How do you think ACOR
will perform against the market?

Top ACOR Bull/Bear Pitches

 

zzlangerhans (< 20)
Submitted October 14, 2010

Acorda seems to be wandering in a sine wave pattern as alternatively optimistic and pessimistic views of the commercial potential of their multiple sclerosis drug Ampyra. Ampyra is far from a proven w … More

0 Replies Reply Report this Post
 

Hogty (< 20)
Submitted September 1, 2009

Overvalued. If you want in on the future of CNS research and production invest in a broader, safer buy like STEM. They will benefit from the production and storage regardless of who comes up with the … More

1 Replies Reply Report this Post

News & Commentary Rss Feed

Meet the Company That's Changing the Multiple Sclerosis Treatment Landscape

With four multiple sclerosis therapies already approved, another under FDA review, and one more in mid-stage studies, this biopharmaceutical company is addressing this disease head on.

This Medical Marijuana Stock Is Not What You Think

GW Pharmaceuticals is more like Biogen, Teva Pharmaceuticals, and Acorda Therapeutics than penny-stock companies hocking medical marijuana.

MannKind Doubles on FDA News, Could Drive Short Covering in Biotech Sector

After a big slump, biotech is having a great week.

Acorda Therapeutics, The Medicines Co. and Shire Plc Could Be Big Movers in Healthcare Today

Today's movers in healthcare and biotechnology.

Sector Update: Healthcare

Sector Update: Healthcare Shares Fairly Flat; Acorda Q4 Earnings Top Street View

Cowen Top Biotech Stocks to Buy for 2014 With Huge Upside

Jazz Pharmaceuticals Isn't Tired of Spending Money

Jazz just made another deal to strengthen its specialty drug franchise. Here's what you need to know.

3 Stocks to Get on Your Watchlist

A rapidly growing Bakken-based oil producer, a possible biotech buyout candidate, and a potentially overvalued paper products company are this week's must-watch stocks.

Acorda Receives Five Awards, Including PM360 Trailblazer Award as Best Specialty Pharma/Biotechnolog

See More ACOR News...

Sector

Healthcare

Industry

Drugs

Acorda Therapeutics, Inc. (ACOR) Description

A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS. Website: http://www.acorda.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks